(24/7 MARKET NEWS) – Mainz Biomed N.V. (NASDAQ:MYNZ) reported, this morning, positive topline results from its ColoFuture study, a multi-center international clinical trial assessing the potential to integrate a portfolio of novel gene expression (mRNA) biomarkers into ColoAlert, the Company’s screening test for colorectal cancer (CRC), which is being commercialized across Europe and other international territories. In addition to reporting sensitivity for colorectal cancer of 94% with a specificity of 97% and a sensitivity for advanced adenoma of 81%, multiple novel mRNA biomarkers were identified for potential integration into pivotal FDA PMA clinical trial (ReconAAsense).
Mainz Biomed is trading at $4.22, up $0.56 (+15.30%), on 1.53M premarket shares traded.
Its 52-week range is $2.8394 to $9.6135. The resistance to $4.75 is low volume and looks to be pretty manageable. If it can break through that on strong volume, the next inflection points are around the $5 and $6 levels.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.